Policymakers in Washington are considering a misguided drug pricing policy—known as the “Most Favored Nation” policy—that would tie the price of medicines in the U.S. to those set by foreign governments. It sounds like a quick fix, but it doesn’t guarantee lower out-of-pocket costs for patients—and it comes with serious risks.

Most Favored Nation pricing would:

• Fail to help patients, with no guarantee of lower costs and risks lowering patient access to treatments and cures.
• Weaken our economy and increase our dependence on China for new treatments.
• Jeopardize future cures by siphoning billions in R&D—money that could go toward medical breakthroughs and U.S. manufacturing.
• Ignore the real cost drivers—middlemen like PBMs and 340B hospital markups that drive up drug costs and foreign countries that don’t pay their fair share to support global R&D.

Instead of importing foreign price controls, policymakers should focus on real solutions that help patients now—like reining in PBMs, holding 340B hospitals accountable and ending foreign freeriding. Other countries should support the innovation they benefit from and if PBMs and tax-exempt 340B hospitals get lower prices, those savings should go to patients.

Take Action Now

Tell your Senator: Reject the Most Favored Nation policies. Say no to foreign reference pricing that harms patients and threatens biopharmaceutical innovation. Instead, support real solutions that put Americans first.